- Home
- GAME vs VTGN Comparison
GAME vs VTGN Comparison
Compare GAME & VTGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | VTGN |
|---|---|---|
| Founded | 2011 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 26.6M | 21.8M |
| IPO Year | 2024 | 2014 |
Fundamental Metrics
Financial Performance| Metric | GAME | VTGN |
|---|---|---|
| Price | $0.25 | $0.57 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $0.90 |
| AVG Volume (30 Days) | ★ 846.7K | 471.6K |
| Earning Date | 05-14-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.72 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,198,101.00 | N/A |
| Revenue This Year | N/A | $124.49 |
| Revenue Next Year | $17.89 | $353.99 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 85.00 | N/A |
| 52 Week Low | $0.26 | $0.43 |
| 52 Week High | $2.87 | $5.14 |
Technical Indicators
Market Signals| Indicator | GAME | VTGN |
|---|---|---|
| Relative Strength Index (RSI) | 33.78 | 40.05 |
| Support Level | N/A | $0.50 |
| Resistance Level | $0.32 | $0.60 |
| Average True Range (ATR) | 0.02 | 0.04 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 3.63 | 6.32 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.